TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29685124

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Analyses System of Psychotherapy (CBASP)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Supportive psychotherapy (SP)
Number of subjects: 255
Study: 29685478

Group type: EXPERIMENTAL
Intervention: Postprandial increase in lipopolysaccharides (LPS) levels in the Incident-DIAB group at baseline
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: LPS postprandial fold change combined with FINDRISC score
Number of subjects: 462

Group type: COMPARATOR
Intervention: FINDRISC score alone
Number of subjects: 462
Study: 29685594

Group type: EXPERIMENTAL
Intervention: Vaxem™ Hib (intramuscular injection)
Number of subjects: 31
Study: 29685860

Group type: EXPERIMENTAL
Intervention: Intensive systolic blood pressure control (goal <120 mm Hg) in ACCORD trial
Number of subjects: 11026

Group type: COMPARATOR
Intervention: Standard systolic blood pressure control (goal <140 mm Hg) in ACCORD trial
Number of subjects: 11026

Group type: EXPERIMENTAL
Intervention: Intensive systolic blood pressure control (goal <120 mm Hg) in SPRINT trial
Number of subjects: 11026

Group type: COMPARATOR
Intervention: Standard systolic blood pressure control (goal <140 mm Hg) in SPRINT trial
Number of subjects: 11026
Study: 29685863

Group type: EXPERIMENTAL
Intervention: iPhone gaming intervention
Number of subjects: 20
Study: 29685882

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 0
Study: 29685935

Group type: EXPERIMENTAL
Intervention: High-Sensitivity Cardiac Troponin T with sex-specific cutoff values
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard High-Sensitivity Cardiac Troponin T cutoff values
Number of subjects: 0
Study: 29686173

Group type: EXPERIMENTAL
Intervention: Insulin treatment for diabetes
Number of subjects: 374
Study: 29686883

Group type: EXPERIMENTAL
Intervention: Penetrating needle group
Number of subjects: 6

Group type: COMPARATOR
Intervention: Skin-touch placebo control group
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 6
Study: 29687077

Group type: EXPERIMENTAL
Intervention: Single-injection intrathecal analgesia (IA)
Number of subjects: 601
Study: 29687277

Group type: EXPERIMENTAL
Intervention: Peripheral perfusion-targeted resuscitation
Number of subjects: 422

Group type: COMPARATOR
Intervention: Lactate-targeted resuscitation
Number of subjects: 422
Study: 29687341

Group type: EXPERIMENTAL
Intervention: Neck circumference
Number of subjects: 120
Study: 29688815

Group type: EXPERIMENTAL
Intervention: Intraventricular infusion of cerliponase alfa (30 mg, 100 mg, or 300 mg, with all patients receiving 300 mg for at least 96 weeks)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intraventricular infusion of cerliponase alfa
Number of subjects: 24

Group type: COMPARATOR
Intervention: Historical controls (42 patients)
Number of subjects: 24
Study: 29688843

Group type: EXPERIMENTAL
Intervention: Quality of life assessment
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Healthcare utilization and costs
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Patient and caregiver preferences
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Bereavement adjustment measurement
Number of subjects: 600
Study: 29689135

Group type: EXPERIMENTAL
Intervention: Intravenous alteplase (0.9mg/kg)
Number of subjects: 80
Study: 29689174

Group type: EXPERIMENTAL
Intervention: Comfortable Cafeteria program led by occupational therapists for 6 weeks
Number of subjects: 0
Study: 29689485

Group type: EXPERIMENTAL
Intervention: High-dose dronabinol (180-240 mg/day; 60-80 mg tid)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Low-dose dronabinol (120 mg/day; 40 mg tid)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 29690880

Group type: EXPERIMENTAL
Intervention: Pulmonary function test (PFT) abnormalities at baseline
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Lower forced expiratory volume in one second after bronchodilator
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: DLCO (carbon monoxide diffusing capacity)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: FeNO
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: PFT results after CCRT
Number of subjects: 52
Study: 29690927

Group type: EXPERIMENTAL
Intervention: Active coil helmet (transcranial LED stimulation, 627 nm, 70 mW/cm²)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Inactive coil (sham)
Number of subjects: 32
Study: 29690930

Group type: EXPERIMENTAL
Intervention: Application of ERTTAC
Number of subjects: 1378

Group type: EXPERIMENTAL
Intervention: Omitting the criterion 'passenger of car or truck'
Number of subjects: 1378
Study: 29691182

Group type: EXPERIMENTAL
Intervention: Adjunctive protective drapes
Number of subjects: 122

Group type: COMPARATOR
Intervention: No adjunctive protective drapes (implied control)
Number of subjects: 122
Study: 29691250

Group type: EXPERIMENTAL
Intervention: Erythropoietin
Number of subjects: 365

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 365
Study: 29691270

Group type: EXPERIMENTAL
Intervention: Combination of high-sensitivity cardiac troponin I (hs-cTnI) and high-sensitivity cardiac troponin T (hs-cTnT) concentrations.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: hs-cTnI and hs-cTnT concentrations with optimized cut-off values (sum: 9 ng/L, product: 18 ng/L).
Number of subjects: 0

Group type: COMPARATOR
Intervention: European Society of Cardiology 2015 guideline recommended algorithms and cut-offs.
Number of subjects: 0
Study: 29691300

Group type: EXPERIMENTAL
Intervention: Andecaliximab/GS-5745 alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Andecaliximab/GS-5745 combined with mFOLFOX6
Number of subjects: 0

Group type: COMPARATOR
Intervention: mFOLFOX6 alone
Number of subjects: 0
Study: 29692311

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis
Number of subjects: 70
Study: 29692935

Group type: EXPERIMENTAL
Intervention: Strontium hydroxyapatite (Sr-HA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Polymethacrylate (PMMA)
Number of subjects: 0
Study: 29692980

Group type: EXPERIMENTAL
Intervention: NCI-sponsored uterine cervix cancer radiation-chemotherapy intervention clinical trial (NCT02466971)
Number of subjects: 0
Study: 29693360

Group type: EXPERIMENTAL
Intervention: EMPA-REG OUTCOME (empagliflozin)
Number of subjects: 23941512

Group type: EXPERIMENTAL
Intervention: VERTIS-CV (ertugliflozin)
Number of subjects: 23941512

Group type: EXPERIMENTAL
Intervention: CANVAS program (canagliflozin)
Number of subjects: 23941512

Group type: EXPERIMENTAL
Intervention: DECLARE-TIMI 58 (dapagliflozin)
Number of subjects: 23941512
Study: 29693361

Group type: EXPERIMENTAL
Intervention: GLP-1 RA CVOTs (including ELIXA, EXSCEL, FREEDOM-CVO, HARMONY Outcomes, LEADER, REWIND, SUSTAIN-6)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EXSCEL (Exenatide Study of Cardiovascular Event Lowering)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ELIXA (lixisenatide)
Number of subjects: 0
Study: 29693476

Group type: EXPERIMENTAL
Intervention: Amoxicillin (1500 mg/d for 7 days)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Vancomycin (1500 mg/d for 7 days)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (1500 mg/d for 7 days)
Number of subjects: 36
Study: 29693715

Group type: EXPERIMENTAL
Intervention: Oral semaglutide (5 mg for 5 days followed by 10 mg for 5 days)
Number of subjects: 56
Study: 29694241

Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Parent Training (PT)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: PT + Placebo
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: PT + ATX
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo alone
Number of subjects: 128
Study: 29694702

Group type: EXPERIMENTAL
Intervention: Aquablation
Number of subjects: 101
Study: 29694948

Group type: EXPERIMENTAL
Intervention: High-sensitivity C-reactive protein (hs-CRP) measurement
Number of subjects: 1301
Study: 29695165

Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 75 mg BID for ≥7 days
Number of subjects: 60
Study: 29695375

Group type: EXPERIMENTAL
Intervention: Wrist cuff blood pressure device (iteratively calibrated)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Wrist cuff blood pressure device (calibrated to direct aortic pressures)
Number of subjects: 20
Study: 29695384

Group type: EXPERIMENTAL
Intervention: Endovascular therapy (thrombectomy, balloon angioplasty, stenting, local fibrinolysis, piercing)
Number of subjects: 2399

Group type: COMPARATOR
Intervention: No endovascular therapy
Number of subjects: 2399

Group type: EXPERIMENTAL
Intervention: Endovascular therapy
Number of subjects: 2399
Study: 29695516

Group type: EXPERIMENTAL
Intervention: INCB040093 100 mg twice daily (monotherapy)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: INCB040093 100 mg twice daily + itacitinib 300 mg once daily (combination)
Number of subjects: 114
Study: 29695812

Group type: EXPERIMENTAL
Intervention: 12 weeks of combined endurance- and strength-exercise intervention
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: One bicycle session
Number of subjects: 26

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 26
Study: 29696165

Group type: EXPERIMENTAL
Intervention: Home Care Aide-led resistance exercise intervention for 6 months
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 126
Study: 29696170

Group type: EXPERIMENTAL
Intervention: All-cause mortality 3 years after the ES index event
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Hospitalization for all causes 3 years after the ES index event
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: ES recurrences
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Unclustered VTs/VFs recurrences
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Hospitalizations for HF worsening
Number of subjects: 500
Study: 29696179

Group type: EXPERIMENTAL
Intervention: Standard-care management for advantaged adolescents (A.S, n=808)
Number of subjects: 1419

Group type: EXPERIMENTAL
Intervention: Standard-care management for less advantaged adolescents (LA.S, n=196)
Number of subjects: 1419

Group type: EXPERIMENTAL
Intervention: Standard and strengthened-care management for less advantaged adolescents (LA.S.S, n=415)
Number of subjects: 1419

Group type: COMPARATOR
Intervention: Standard-care management (control)
Number of subjects: 1419
Study: 29696198

Group type: EXPERIMENTAL
Intervention: PAX Good Behavior Game (PAX GBG) intervention
Number of subjects: 42

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 42
Study: 29696202

Group type: EXPERIMENTAL
Intervention: Topical antiviral drug AV2
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29696203

Group type: EXPERIMENTAL
Intervention: CREATE Wellness intervention (3 session, group-based intervention)
Number of subjects: 0
Study: 29696211

Group type: EXPERIMENTAL
Intervention: Presurgical lifestyle intervention trials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 29696228

Group type: EXPERIMENTAL
Intervention: Structured physical activity in the LIFE study
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Oral cranberry capsules in the CRANNY trial
Number of subjects: 385

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 385
Study: 29696238

Group type: EXPERIMENTAL
Intervention: Gender- and culturally-sensitive weight loss intervention (GCSWLI) for 24 weeks, including a 12-week in-person phase with weekly sessions and a 12-week follow-up with bi-weekly phone calls.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Wait-list control (WLC) group received no intervention during the initial 24 weeks but later received the GCSWLI plus mobile health technology support.
Number of subjects: 50
Study: 29696581

Group type: EXPERIMENTAL
Intervention: Cardiopulmonary bypass (CPB)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Erythropoietin
Number of subjects: 64
Study: 29698249

Group type: EXPERIMENTAL
Intervention: Greater number of invasive procedures
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Greater anxiety recalled about infant's invasive procedures
Number of subjects: 36
Study: 29699410

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 0
Study: 29699477

Group type: EXPERIMENTAL
Intervention: Bacterial translocation positive (bactDNA(+)) patients
Number of subjects: 30

Group type: COMPARATOR
Intervention: Bacterial translocation negative (bactDNA(-)) patients
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups (bactDNA(+) and bactDNA(-))
Number of subjects: 30
Study: 29699493

Group type: EXPERIMENTAL
Intervention: Adherence to current antimicrobial guidelines (2016 Chinese CAP guidelines)
Number of subjects: 3131

Group type: COMPARATOR
Intervention: Non-adherent treatment (62.1% of patients)
Number of subjects: 3131

Group type: COMPARATOR
Intervention: Over-treatment in general-ward patients (52.3% over-treated)
Number of subjects: 3131

Group type: COMPARATOR
Intervention: Under-treatment in ICU patients (71.4% under-treated)
Number of subjects: 3131

Group type: COMPARATOR
Intervention: Under-treatment in general-ward patients with risk factors for PA infection (22.9% under-treated)
Number of subjects: 3131

Group type: COMPARATOR
Intervention: Under-treatment in ICU patients with risk factors for PA infection (74.2% under-treated)
Number of subjects: 3131
Study: 29699498

Group type: EXPERIMENTAL
Intervention: Echocardiographic response (E+)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Biomarker response (B+)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Clinical response (C+)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Echocardiographic responders (E+)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Clinical responders (C+)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Non-responders (E-/C-)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Biomarker response
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Clinical response
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Composite score of response measures
Number of subjects: 202
Study: 29699614

Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold (BVS) implantation
Number of subjects: 20
Study: 29699913

Group type: EXPERIMENTAL
Intervention: Indoor environmental pollutants (EPS)
Number of subjects: 718

Group type: COMPARATOR
Intervention: Outdoor air pollutants
Number of subjects: 718
Study: 29699961

Group type: EXPERIMENTAL
Intervention: Social networking-based intervention (Facebook)
Number of subjects: 24
Study: 29700101

Group type: EXPERIMENTAL
Intervention: Decision aid (DA) in combination with a brief Q&A session with a genetic counsellor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Genetic counselling alone
Number of subjects: 0
Study: 29700172

Group type: EXPERIMENTAL
Intervention: Post-transplant infusion of cyclophosphamide
Number of subjects: 0
Study: 29700872

Group type: EXPERIMENTAL
Intervention: Omalizumab-supplemented Oral Immunotherapy (OIT)
Number of subjects: 13
Study: 29701105

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 299
Study: 29701107

Group type: EXPERIMENTAL
Intervention: Adjunctive naturopathic oncology (NO) specialty care
Number of subjects: 2

Group type: COMPARATOR
Intervention: Standard oncologic care
Number of subjects: 2
Study: 29701939

Group type: EXPERIMENTAL
Intervention: Bilateral rTMS
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Left unilateral rTMS
Number of subjects: 156

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 156

Group type: COMPARATOR
Intervention: Bilateral rTMS vs Sham rTMS
Number of subjects: 156

Group type: COMPARATOR
Intervention: Left unilateral rTMS vs Sham rTMS
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Change in suicidal ideation
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Change in HDRS-16 score
Number of subjects: 156
Study: 29702001

Group type: COMPARATOR
Intervention: MC1.0
Number of subjects: 131

Group type: COMPARATOR
Intervention: CMC
Number of subjects: 131
Study: 29702295

Group type: EXPERIMENTAL
Intervention: IBS-FD (patients with functional dyspepsia)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: IBS (patients without functional dyspepsia)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Anxiety levels
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Somatization severity
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Exhaled hydrogen levels
Number of subjects: 205
Study: 29703168

Group type: EXPERIMENTAL
Intervention: Screen-based media consumption (TV/video, game console, PC/internet, mobile phone)
Number of subjects: 850

Group type: EXPERIMENTAL
Intervention: Lower consumption of computers/internet
Number of subjects: 850

Group type: EXPERIMENTAL
Intervention: Lower consumption of TV/video and higher frequency of non-organized physical activity
Number of subjects: 850

Group type: EXPERIMENTAL
Intervention: Non-organized physical activity
Number of subjects: 850

Group type: EXPERIMENTAL
Intervention: Media consumption
Number of subjects: 850

Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 850
Study: 29703211

Group type: EXPERIMENTAL
Intervention: Pain
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Lower level of education
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Blood pressure
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Higher blood pressure
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Living alone
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Higher diastolic blood pressure
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Higher body mass index
Number of subjects: 502
Study: 29703235

Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis ssp. lactis B94
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 29703237

Group type: EXPERIMENTAL
Intervention: Community Wise intervention (various components including peer or licensed facilitator, group dialogue, personal goal development, community organizing, and a core critical-thinking component)
Number of subjects: 528

Group type: COMPARATOR
Intervention: Standard of care (not specified in detail)
Number of subjects: 528
Study: 29703712

Group type: EXPERIMENTAL
Intervention: Topically applied growth factors combined with protease inhibitor wound dressings
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topically applied growth factors with standard wound dressings
Number of subjects: 0
Study: 29703778

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV) plus bendamustine
Number of subjects: 55
Study: 29703852

Group type: EXPERIMENTAL
Intervention: Early Warning Scores (EWS)
Number of subjects: 16386

Group type: EXPERIMENTAL
Intervention: Physiological parameters
Number of subjects: 16386
Study: 29703851

Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplantation (FMT) from an anonymous healthy donor
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups continue weekly self-administered subcutaneous MTX treatment (15-25 mg/week)
Number of subjects: 80
Study: 29705220

Group type: EXPERIMENTAL
Intervention: Macitentan 10 mg
Number of subjects: 278
Study: 29705219

Group type: EXPERIMENTAL
Intervention: Flow cytometry assessment of CD64 levels
Number of subjects: 781

Group type: EXPERIMENTAL
Intervention: Flow cytometry assessment of circulating IGs
Number of subjects: 781
Study: 29705265

Group type: EXPERIMENTAL
Intervention: GS-0976 20 mg orally once daily for 12 weeks
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: GS-0976
Number of subjects: 10

Group type: COMPARATOR
Intervention: Healthy volunteers (controls), n = 10
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Patients with NASH
Number of subjects: 10
Study: 29705733

Group type: EXPERIMENTAL
Intervention: Vaginal oestrogen ring used continuously for 8 years
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Surgery (cruciate incision in the cervicovaginal scar)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Topical immunosuppression for GVHD
Number of subjects: 1
Study: 29705753

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moderate-intensity continuous training (CT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HIIT combined with fasting
Number of subjects: 0

Group type: COMPARATOR
Intervention: CT combined with fasting
Number of subjects: 0
Study: 29705765

Group type: EXPERIMENTAL
Intervention: Invasive mechanical ventilation
Number of subjects: 0
Study: 29706375

Group type: EXPERIMENTAL
Intervention: Balixafortide plus eribulin
Number of subjects: 56

Group type: COMPARATOR
Intervention: Eribulin
Number of subjects: 56

Group type: COMPARATOR
Intervention: Balixafortide
Number of subjects: 56
Study: 29706508

Group type: EXPERIMENTAL
Intervention: Hybrid CTO PCI
Number of subjects: 3055

Group type: EXPERIMENTAL
Intervention: Antegrade wire escalation
Number of subjects: 3055

Group type: EXPERIMENTAL
Intervention: Retrograde strategy
Number of subjects: 3055

Group type: EXPERIMENTAL
Intervention: Antegrade dissection re-entry
Number of subjects: 3055

Group type: EXPERIMENTAL
Intervention: Multiple crossing strategies
Number of subjects: 3055

Group type: EXPERIMENTAL
Intervention: Contrast volume
Number of subjects: 3055

Group type: EXPERIMENTAL
Intervention: Air kerma radiation dose
Number of subjects: 3055

Group type: EXPERIMENTAL
Intervention: Procedure time
Number of subjects: 3055

Group type: EXPERIMENTAL
Intervention: Fluoroscopy time
Number of subjects: 3055
Study: 29706550

Group type: EXPERIMENTAL
Intervention: Aging (comparison between younger and older adults)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Twin cohort analysis
Number of subjects: 0
Study: 29706993

Group type: EXPERIMENTAL
Intervention: Standing on a moving platform
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional balance exercises
Number of subjects: 0
Study: 29706998

Group type: EXPERIMENTAL
Intervention: Melatonin (3 mg/day)
Number of subjects: 17
Study: 29707200

Group type: EXPERIMENTAL
Intervention: Simvastatin administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0